Treats superficial infections of the external auditory canal caused by organisms…. Sold as Vosol HC. Every FDA application for this active ingredient: 1 branded and 7 generic.
As of Nov 22, 2026, FDA lists 8 applications for Acetic acid, glacial; Hydrocortisone (sold as Vosol HC), first approved Jun 23, 1961, with 0 new uses approved and 0 published complete response letters.
| Jun 23, 1961 | Vosol HCNDA 12770 · New combination | Saptalis Pharmaceuticals | 19 | Marketed |
| May 10, 1977 | Acetic Acid W/ HydrocortisoneANDA 85492 | KV Pharmaceutical | 0 | Discontinued |
| Mar 3, 1980 | Orlex HCANDA 86844 | Warner Chilcott | 0 | Discontinued |
| Jan 13, 1982 | Acetasol HCANDA 87143 | Actavis Mid Atlantic | 13 | Discontinued |
| Mar 4, 1985 | Hydrocortisone and Acetic AcidANDA 88759 | Taro Pharmaceuticals | 15 | Marketed |
| Aug 30, 1996 | Hydrocortisone and Acetic AcidANDA 40168 | Wockhardt | 1 | Discontinued |
| Feb 6, 2006 | Hydrocortisone and Acetic AcidANDA 40609 | Cosette Pharmaceuticals | 0 | Marketed |
| — | Hydrocortisone and Acetic AcidANDA 40097 | Bausch & Lomb | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA